Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

share with twitter share with LinkedIn share with facebook
01/22/2020 | 08:39am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the ''Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Receipt of Approval for Drug Clinical Trial from FDA by a Subsidiary'' published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

22 January 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang and Ms. Mu Haining; and the independent non- executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

  • for identification purposes only

Stock code: 600196 Stock abbreviation: Fosun Pharma Annoucement No.: 2020-009

Bond code: 136236 Bond abbreviation: 16Fosun01

Bond code: 143020 Bond abbreviation: 17Fosun01

Bond code: 143422 Bond abbreviation: 18Fosun01

Bond code: 155067 Bond abbreviation: 18Fosun02

Bond code: 155068 Bond abbreviation: 18Fosun03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Receipt of Approval for Drug Clinical Trial from FDA by a Subsidiary

The board of directors (the "Board") of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Fochon Pharmaceuticals, Ltd.* (重慶復創醫藥研究有限公司) ("Fochon Pharma"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), has received a letter numbered IND145732 of approval for clinical trial for SAF-189 (namely Furuitini Succinate or the "New Drug") for the treatment of tumors from the FDA (i.e. U.S. Food and Drug Administration). Fochon Pharma intends to conduct clinical trial for the New Drug in the United States upon meeting the conditions shortly.

II. Research Progress of the New Drug

The New Drug is an innovative small molecule chemical drug researched and developed by Fochon Pharma and Shanghai Institute of Materia Medica, Chinese Academy of Sciences mainly for the treatment of tumors. As at the date of this announcement, Furuitini Succinate capsules for the treatment of tumors is in phase I clinical trial in PRC (excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan region).

As at the date of this announcement, drugs with the same target as the New Drug have been marketed in the global market. According to the latest data from IQVIA MIDASTM provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and healthcare industry, the worldwide sales of the drugs with the same target as the New Drug amounted to approximately US$1,152.68 million in 2018.

Up until December 2019, the cumulative R&D investment of the Group (i.e. the Company and controlling subsidiaries/units) in the New Drug was approximately RMB85.84 million (unaudited) at this stage.

1

III.Risk Warning

Based on our experience in new drug research and development, there are certain risks in new drug development. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

As required by the laws and regulations relating to new drug research and development in the United States, the New Drug is subject to a series of clinical studies and the approval from the drug evaluation authority before it can be marketed.

The research and development and marketing of new drugs are a long-term task involving various uncertainties. Investors are reminded of the investment risks.

Annoucement is hereby given.

Board of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

22 January 2020

* for identification purposes only

2

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 22 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 January 2020 13:38:04 UTC

share with twitter share with LinkedIn share with facebook
Latest news on SHANGHAI FOSUN PHARMACEUTI
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
06/29Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech
RE
04/29Shanghai Fosun Pharmaceutical 1Q Net Fell 19% on Higher Research Expenses
DJ
03/30Shanghai Fosun Pharmaceutical 2019 Net Profit Rises 23%
DJ
03/20SHANGHAI FOSUN PHARMACEUTICAL GROUP : annual earnings release
03/18SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - the progress of the pla..
PU
03/18SHANGHAI FOSUN PHARMACEUTICAL : Date of board meeting(h shares)
PU
03/17Pfizer, BioNTech to co-develop potential coronavirus vaccine
RE
03/16BioNTech in China alliance with Fosun over potential coronavirus vaccine
RE
03/15SHANGHAI FOSUN PHARMACEUTICAL : OVERSEAS REGULATORY ANNOUNCEMENT - Announcement ..
PU
More news
Financials
Sales 2020 32 408 M 4 626 M 4 626 M
Net income 2020 3 526 M 503 M 503 M
Net Debt 2020 13 549 M 1 934 M 1 934 M
P/E ratio 2020 25,9x
Yield 2020 1,14%
Capitalization 86 390 M 12 353 M 12 333 M
EV / Sales 2019
EV / Sales 2020 3,08x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 31,82 CNY
Last Close Price 36,00 CNY
Spread / Highest target 16,7%
Spread / Average Target -11,6%
Spread / Lowest Target -40,4%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP